Last updated: February 19, 2026
This report analyzes the key suppliers and the patent landscape for fosaprepritant dimeglumine, a critical antiemetic agent used in chemotherapy. Understanding supplier capabilities and patent protection is essential for pharmaceutical companies managing R&D pipelines and investment strategies.
What is Fosaprepitant Dimeglumine?
Fosaprepritant dimeglumine is an intravenous prodrug of aprepitant, a selective neurokinin-1 (NK1) receptor antagonist. It is primarily used for the prevention of chemotherapy-induced nausea and vomiting (CINV). The drug's mechanism involves blocking the action of substance P, a key neurotransmitter in the emetic pathway. Fosaprepritant is converted to aprepitant in the body after administration.
Key Suppliers of Fosaprepritant Dimeglumine API
The supply chain for Active Pharmaceutical Ingredients (APIs) is complex and often involves specialized manufacturers. For fosaprepritant dimeglumine, the primary suppliers are contract development and manufacturing organizations (CDMOs) and API manufacturers with expertise in complex organic synthesis.
Table 1: Identified Fosaprepritant Dimeglumine API Suppliers
| Supplier Name |
Location |
Key Capabilities |
Notes |
| Sterop |
Belgium |
API manufacturing, custom synthesis, regulatory support |
Identified as a supplier for the branded product. |
| Cosette Pharmaceuticals |
USA |
API sourcing, finished dosage form manufacturing |
Engaged in the generic market for aprepitant. Potential for fosaprepritant API sourcing. |
| Divi's Laboratories |
India |
Large-scale API manufacturing, multiple therapeutic areas |
Known for chiral synthesis and complex chemistry. |
| WuXi AppTec |
China/USA |
CDMO services, process development, clinical to commercial |
Offers comprehensive API development and manufacturing solutions. |
| Lonza |
Switzerland |
API manufacturing, biologics, small molecules |
Global CDMO with extensive experience in pharmaceutical manufacturing. |
Source: Company websites, industry databases, regulatory filings.
These suppliers possess the chemical synthesis expertise and Good Manufacturing Practice (GMP) compliance required for pharmaceutical API production. Their capacity and regulatory track record are critical factors for pharmaceutical companies seeking reliable sourcing.
The Patent Landscape for Fosaprepritant Dimeglumine
The patent landscape for fosaprepritant dimeglumine is crucial for understanding market exclusivity, potential for generic entry, and opportunities for life cycle management. Patents can cover the compound itself, its salts, polymorphs, synthetic routes, formulations, and methods of use.
Compound and Formulation Patents
The original patents protecting aprepitant and its prodrugs are foundational. Fosaprepritant dimeglumine itself is protected by patents that define its chemical structure and specific salt form.
- Emend (Merck & Co.) was the original branded product for aprepitant. Patents related to aprepitant's discovery and early formulations are held by Merck.
- Fosaprepitant Dimeglumine Specific Patents: Patents specifically claim the dimeglumine salt of fosaprepritant, which offers improved solubility and stability for intravenous administration compared to free fosaprepritant. These patents have been critical in defining the market exclusivity for this specific salt form.
Example Patent Claims: Patents often claim "A salt of fosaprepritant with meglumine" or "Fosaprepritant dimeglumine." Further claims can detail specific crystalline forms, solvates, or purification methods.
Manufacturing Process Patents
Beyond the compound itself, innovative methods of synthesizing fosaprepritant and its dimeglumine salt are also patentable. These process patents can provide a second layer of protection, even after the primary compound patent expires, by making it difficult for competitors to manufacture the drug without infringing on the manufacturing route.
- Key Synthesis Steps: The synthesis of fosaprepritant involves multiple chiral centers and complex coupling reactions. Patents may focus on specific catalysts, reagents, reaction conditions, or purification techniques that improve yield, purity, or cost-effectiveness.
- Polymorph Patents: Different crystalline forms (polymorphs) of fosaprepritant dimeglumine can have distinct physical properties, such as dissolution rates and stability. Companies may secure patents on novel, advantageous polymorphs.
Method of Use Patents
Patents related to specific indications or patient populations can extend market exclusivity. For fosaprepritant dimeglumine, these would primarily relate to the prevention of CINV, potentially with specific breakdowns based on the type of chemotherapy or patient risk factors.
Patent Expiration and Generic Entry
The expiration of key patents significantly impacts the market by allowing generic manufacturers to enter. The timeline for patent expiration is a critical factor for R&D and investment decisions.
Timeline Considerations:
- Original Compound Patents: Expired or nearing expiration for aprepitant and early fosaprepritant formulations.
- Dimeglumine Salt Patents: These have historically provided extended exclusivity for the specific intravenous formulation.
- Process and Polymorph Patents: These can offer further protection and may expire later than the compound patents.
Companies looking to enter the generic market must conduct thorough freedom-to-operate (FTO) analyses to ensure their manufacturing processes and formulations do not infringe on existing, valid patents.
Key Patent Holders and Strategies
Major pharmaceutical companies, particularly Merck & Co. (originator of aprepitant), have historically held significant patent portfolios for fosaprepritant dimeglumine. Their strategies often involve:
- Broad Patent Filings: Securing patents on various aspects of the drug, including different salt forms, polymorphs, and synthetic routes.
- Evergreening: Filing for new patents on incremental improvements or new uses to extend market exclusivity.
- Litigation: Defending patents against generic challenges.
Generic manufacturers, on the other hand, focus on:
- Non-infringing Processes: Developing alternative synthetic routes that bypass existing process patents.
- Challenging Patents: Seeking to invalidate existing patents through legal means.
- Developing Bioequivalent Formulations: Creating generic versions that meet regulatory standards for equivalence.
Regulatory Status and Approval Pathways
Fosaprepritant dimeglumine is approved in major markets for the prevention of CINV. Regulatory filings with agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) contain detailed information on approved indications, dosage, and manufacturing standards.
- FDA Approval: The FDA approves drugs based on safety and efficacy data. Generic versions require an Abbreviated New Drug Application (ANDA) demonstrating bioequivalence to the reference listed drug.
- EMA Approval: Similar to the FDA, the EMA requires robust data for marketing authorization.
The regulatory landscape also includes patent linkage, where regulatory approval can be tied to patent status. For example, in the U.S., the Hatch-Waxman Act provides mechanisms for patent protection during the regulatory review process.
Market Dynamics and Competitive Landscape
The market for antiemetics, particularly for CINV, is significant. Fosaprepritant dimeglumine competes with other NK1 receptor antagonists, 5-HT3 receptor antagonists, and corticosteroids.
- Branded vs. Generic: The market shifts considerably with the entry of generics, leading to price erosion and increased volume.
- Therapeutic Area Growth: The increasing incidence of cancer and advancements in chemotherapy regimens drive demand for effective CINV management.
Understanding the competitive landscape requires monitoring not only existing products but also the pipelines of other pharmaceutical companies for novel antiemetic agents.
Key Takeaways
- Fosaprepritant dimeglumine is a critical intravenous antiemetic.
- Sterop is a key identified supplier for the branded API. Other CDMOs like WuXi AppTec and Lonza offer manufacturing services.
- The patent landscape includes claims on the compound, its dimeglumine salt, manufacturing processes, and polymorphs.
- Patent expiry is a critical driver for generic market entry, necessitating thorough freedom-to-operate analyses.
- Merck & Co. has been a primary patent holder, employing strategies to extend market exclusivity.
- Generic manufacturers focus on developing non-infringing processes and demonstrating bioequivalence.
- Regulatory approvals and patent linkage significantly influence market dynamics.
Frequently Asked Questions
1. Which companies are authorized to manufacture fosaprepritant dimeglumine API under GMP conditions?
While specific authorization is proprietary, companies with broad API manufacturing capabilities and a history of supplying to regulated markets are typically engaged. Sterop is a known supplier. Large CDMOs like WuXi AppTec and Lonza also possess the necessary certifications and expertise.
2. What are the primary challenges in synthesizing fosaprepritant dimeglumine?
The synthesis involves complex stereochemistry, requiring precise control over reaction conditions to achieve high enantiomeric purity. The formation of the dimeglumine salt also demands specific crystallization techniques to ensure desired physical properties and stability.
3. How does the patent expiry of fosaprepritant dimeglumine impact market pricing?
Upon the expiration of key patents, generic versions can be introduced, leading to significant price competition. This typically results in a substantial reduction in the price of the drug as multiple manufacturers vie for market share.
4. What is the significance of the dimeglumine salt in fosaprepritant formulations?
The dimeglumine salt is crucial for improving the solubility and stability of fosaprepritant, making it suitable for intravenous administration. This specific salt form often has its own patent protection, extending the exclusivity period beyond the basic compound patent.
5. What due diligence is required before a generic company can launch a fosaprepritant dimeglumine product?
Generic companies must conduct comprehensive freedom-to-operate analyses to ensure they are not infringing on any active patents related to the compound, its salt form, manufacturing processes, or specific indications. They also need to establish bioequivalence to the reference listed drug and obtain regulatory approval from agencies like the FDA or EMA.
Citations
[1] Merck & Co., Inc. (n.d.). Emend (aprepitant) Prescribing Information.
[2] Sterop. (n.d.). Active Pharmaceutical Ingredients. Retrieved from https://www.sterop.com/
[3] Cosette Pharmaceuticals. (n.d.). Products. Retrieved from https://cosette.com/
[4] Divi's Laboratories. (n.d.). Product Portfolio. Retrieved from https://www.divis.com/
[5] WuXi AppTec. (n.d.). Small Molecule Drug Development & Manufacturing. Retrieved from https://www.wuxiapptec.com/
[6] Lonza. (n.d.). Small Molecules. Retrieved from https://www.lonza.com/
[7] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/
[8] European Medicines Agency. (n.d.). Human Medicines. Retrieved from https://www.ema.europa.eu/
